Creabilis expands senior management team
This article was originally published in Scrip
Earlier in August, Creabilis hired David Roblin from Pfizer as chief medical officer (scripintelligence.com, 9 August), and now, the company has appointed three more ex-Pfizer employees to its senior management team. Alex Leech joins Creabilis as vice-president and head of finance and operations, and previously served as head of operations at Solace Pharmaceuticals, and head of European project management for the Pfizer R&D organisation. James Sandy was most recently development team leader at Pfizer, and joins Creabilis as senior vice-president and head of development, and Dr Peter Spargo, former head of chemical process R&D for Pfizer, joins as senior vice-president of CMC, the same role he held recently at Novexel.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.